Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer ...

Among 997 patients with lung cancer, only 35.1% met USPSTF screening criteria, while universal age-based screening (40-85 ...

Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and ...

A trace of blood in the stool, a mild stomach ache, and a persistent urge to pass motion. Most Malaysians would dismiss these ...

The second-most common cancer in Malaysia may not have symptoms, which is why experts advocate checkups for early detection.

Colon cancer is one of the most common types of cancer in the UK - and one doctor has outlined six key symptoms you should ...

Madison-based Exact Sciences will be acquired by Abbott Laboratory for roughly $23 billion in a deal that was announced Nov.

By bringing Exact Sciences into the fold, the expectation is that the focus on cancer diagnostics can provide a jolt to the ...

In the UK around 44,100 people are diagnosed with cancer in the colon or rectum every year, making it the fourth most common form of the disease in Britain, according to Cancer Research UK ...

Five AI-based technologies that can be used during a colonoscopy exam to help detect the early signs of bowel cancer have ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...